D.Western Therapeutics Institute Inc
TSE:4576
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| JP |
D
|
D.Western Therapeutics Institute Inc
TSE:4576
|
5.2B JPY |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
370.2B USD |
Loading...
|
|
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
356.2B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
166.6B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
69B AUD |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -179.8% |
| 30th Percentile | 21.8% |
| Median | 30.6% |
| 70th Percentile | 42.3% |
| Max | 18 197.9% |
Other Profitability Ratios
D.Western Therapeutics Institute Inc
Glance View
D. Western Therapeutics Institute, Inc. engages in the research and development of pharmaceutical drugs. The company is headquartered in Nagoya, Aichi-Ken and currently employs 19 full-time employees. The company went IPO on 2009-10-23. The firm generates revenue from licensing of its developed drugs to other companies. As of December 31, 2012, the Company’s drug pipeline included anti-thrombotic medicine K-134, therapeutic agent K-115 for glaucoma, and anticancer drug HMN-214. Its newly-developed products include new anti-thrombotic medicine and signal-transduction inhibitors, including therapeutic agent for high-blood pressure, protective agent for nerves, therapeutic agent for atherosclerosis, ophthalmologic drug and anticancer drug, among others. The firm is also developing new drug candidate compounds focusing on protein kinase inhibitors and involving in ophthalmic surgical adjuvant business, which includes ingredient of Brilliant Blue G-250.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for D.Western Therapeutics Institute Inc is 90%, which is below its 3-year median of 91%.
Over the last 3 years, D.Western Therapeutics Institute Inc’s Gross Margin has decreased from 93.8% to 90%. During this period, it reached a low of 89.1% on Jun 30, 2025 and a high of 93.8% on Dec 31, 2022.
